AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03347292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib(Stivarga, BAY73-4506)
Description: Regorafenib 80mg/120mg/160mg q.d., 3 weeks on / 1 week off + pembrolizumab 200mg i.v. every 3 weeks
Study NCT03347292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg i.v.(Intravenous(ly)) every 3 weeks (Q3W). This dose will not be escalated or deescalated and the dosing schedule will not be changed
Study NCT03553992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POP-6:
Description: 90 days of Facebook messaging, weekly live sessions targeting tobacco use and tailored to SGM young adults~Drug: nicotine patch 14-day supply of nicotine patch
Study NCT03553992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TSP-6:
Description: 90 days of Facebook messaging, weekly live sessions targeting tobacco use~Drug: nicotine patch 14-day supply of nicotine patch
Study NCT03118661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: For Step 2: Structured treatment interruption
Description: -Accepted tool in the evaluation of immunological interventions, gene therapy, or therapeutic vaccines for the treatment of HIV infection
Study NCT03118661 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood draw
Description: -Screening, entry for Step 1, Step 1 visit 2, entry for Step 2, weekly, week 16, monthly through week 52, week 52, quarterly through year 5, year 5, and viral relapse
Study NCT03649308 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy
Description: An immediate mobilization and negative pressure wound therapy (PICO) initiated after surgery.
Study NCT03649308 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Traditional treatment with conventional wound dressing and 5 days of immobilization after surgery.
Study NCT01429025 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: IV
Study NCT01429025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine
Description: IV
Study NCT01429025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: PO
Study NCT03393247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: infliximab and azathioprine combination at week 0
Description: All enrolled CD patients will schedule on IF X (week 0, 2, 6 and then every 8 weeks at 5mg/kg).Experimental group will receive azathioprine at week 0.
Study NCT03393247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: infliximab and azathioprine combination at week 14
Description: All enrolled CD patients will schedule on IF X (week 0, 2, 6 and then every 8 weeks at 5mg/kg).Control group will receive azathioprine at week 14.
Study NCT00740935 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Rotateq vaccine
Description: Vaccination against rotavirus~Three oral doses (2 mL) between 6 to 26 weeks of life with at least 4 weeks between each dose.
Study NCT04682119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3526318
Description: Administered orally.
Study NCT04682119 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study NCT04321135 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Lifestyle Program Intervention
Description: The Guided Lifestyle Program will receive sessions that meet twice weekly and 2-3 text messages weekly.They will also receive a participant informational binder (wellness guide) with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.
Study NCT04321135 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Guided Lifestyle Program (Control Arm)
Description: In the self-guided weight loss program, participants will be given the sane informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines but they will not receive in-person classes or text messaging
Study NCT02537158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: sorafenib group patients will accept sorafenib therapy for one year（400 mg bid,orally).
Study NCT02537158 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE group patients will accept TACE therapy once at a month after resection.
Study NCT04385693 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulpotomy
Description: Pulpotomy using bioactive bioceramic cement of 1.5 mm layer of a newly FDA approved calcium-based silicate cement (Nusmile NeoPutty) will be placed on the pulp chamber floor and canals' orifices for pulp and root therapy. Pulpotomy is a procedure in which the coronal pulp is amputated, and the remaining radicular pulp tissue is treated with a medicament to preserve the pulp's health.This technique involves administration of local analgesia, Isolation of the tooth with rubber dam, complete caries removal and then access to the pulp chamber using drills.
Study NCT04385693 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extraction and placement of space maintainer
Description: If during the pulpotomy procedure, hemostasis is not obtainable, or signs of advanced pulp degeneration such as dark and limited or no bleeding from canals, the pulp will be diagnosed as chronically inflamed or necrotic, and tooth will be extracted. As part of the standard of care after extractions of primary molars, space maintenance will be assessed, and a space maintainer fabricated if indicated. Extracted teeth will serve as controls, and information regarding the need or not of space maintenance.
Study NCT01528202 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cherry juice
Description: 30 mLs preceding morning meal and 30 mLs preceding evening meal each day for 7 days.
Study NCT01528202 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fruit juice cordial
Description: fruit flavoured juice concentrate
Study NCT04854447 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single-Vision Spectacles
Description: Spectacle correction for myopia treatment
Study NCT04854447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single-Vision Spectacles
Description: Spectacle correction for myopia treatment
Study NCT06131476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blink® Tears eye drops
Description: Control Drops
Study NCT01254279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CABAZITAXEL
Description: Pharmaceutical form: Concentrate For Solution For Infusion Route of administration: Intravenous
Study NCT05250661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aqueous propolis extract
Description: The patients gargled 4 times a day after meals and 5 ml each time. Patients were instructed to keep the propolis solution in their mouth for one minute, to touch all structures in the mouth, and not to eat or drink anything orally for one hour after spitting.
Study NCT01486199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Absorptive clearance scan
Description: Subjects will inhale a nebulized mixture of the radiopharmaceuticals Indium 111-DTPA and Technetium 99m-sulfur colloid.
Study NCT00820755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab plus Platinum-based Doublet Chemotherapy
Description: Single first dose of cetuximab 400 mg/m\^2 infusion will be administered intravenously over 120 minutes (min) followed by cetuximab 250 mg/m\^2 intravenous infusion over 60 min q1w with background platinum-based doublet chemotherapy up to maximum of 6 cycles, until progressive disease, unacceptable toxicity, or withdrawal of consent. Platinum based doublet chemotherapy will be administered as intravenous infusion as per study center included: vinorelbine 25 mg/m\^2 on Day 1 (D1) and Day 8 (D8)+cisplatin 80 mg/m\^2 on D1; or gemcitabine 1250 mg/m\^2 on D1 and D8+cisplatin 75 mg/m\^2 on D1; or gemcitabine 1000 mg/m\^2 on D1 and D8+carboplatin at dose to reach area under curve (AUC)5 milligram\*hour/milliliter (mg\*hr/mL) on D1; or Docetaxel 75 mg/m\^2 on D1+cisplatin 75 mg/m\^2 on D1; or paclitaxel 175 mg/m\^2 on D1+cisplatin 80 mg/m\^2 on D1; or paclitaxel 200 mg/m\^2 on D1+carboplatin at dose to reach AUC6 mg\*hr/mL on D1, of each 3-week treatment cycle for a maximum of 6 cycles.
Study NCT00820755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab 500 mg/m^2
Description: Subjects who will be free of disease progression at the end of combination therapy, will enter in the maintenance therapy period. In the maintenance period, subjects will be receive cetuximab 500 mg/m\^2 as intravenous infusion every 2 weeks, until progressive disease (PD), unacceptable toxicity, or withdrawal of consent.
Study NCT00820755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab 250 mg/m^2
Description: Subjects who will free of disease progression at the end of combination therapy, will enter in the maintenance therapy period. In the maintenance period, subjects will be receive cetuximab 250 mg/m\^2 as intravenous infusion weekly, until PD, unacceptable toxicity, or withdrawal of consent.
Study NCT01092845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04457845 / matched placebo
Description: PF-04457845 4 mg tablet once daily / matched placebo
Study NCT03694925 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Calprotectin test
Description: Calprotectin will be measured both by ELISA and point of care test.
Study NCT01422239 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored treatment
Description: 8 sessions of individual behavioral counseling. The first 3 sessions will be 45 minutes long and include 30 minutes tailored to the perceived risks of quitting most strongly held by each participant. The final 5 sessions will be 30 minutes long and include material from the Mayo Clinic's smoking cessation manual.
Study NCT01422239 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: 8 sessions of individual behavioral counseling. The first 3 sessions will be 45 minutes long and include 30 minutes focused on the benefits of quitting smoking. The final 5 sessions will be 30 minutes long and include material from the Mayo Clinic's smoking cessation manual.
Study NCT02624037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized Dosage Precision IFX Dashboard
Description: Pharmacokinetic Dashboard Recommended Dosage and Dosing Frequency of Infliximab
Study NCT01638780 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A placebo will given for 30 days, twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.
Study NCT01638780 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: resveratrol
Description: resveratrol will be given for 30 days, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.
Study NCT01051141 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer-delivered Brief Intervention (CBI)
Description: The multimedia, interactive CBI condition will be delivered using touch-screen tablet computers with audio delivered via headphones. The interventions are highly individualized and designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant.
Study NCT01051141 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervener-delivered Brief Intervention (IBI)
Description: The IBI condition will be delivered by a master's-level clinician with the aid of graphics. The interventions are highly individualized and designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant.
Study NCT01051141 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adapted Motivational Enhancement Therapy (AMET)
Description: The AMET session will have a similar general outline (\~45 minutes) to the BI in the ED, including a review of participants' goals and values, alcohol use and consequences, decisional balance exercises, and change plan.
Study NCT00717600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1
Description: 2x10\^9 cfu of Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1 administered daily via a single orally ingested freeze-dried capsule.
Study NCT02924662 — intervention group
Intervention type: OTHER
Intervention: There is no intervention.
Study NCT04429126 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acupressure
Description: Two types acupressure interventions, 5-point and 2-point acupressure groups, will be conducted in the current study.
Study NCT04429126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Two types acupressure interventions, 5-point and 2-point acupressure groups, will be conducted in the current study.
Study NCT00837785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00012
Description: 240 mg (two 120 mg capsules) orally three times a day
Study NCT00837785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00012
Description: 240 mg (two 120 mg capsules) orally twice a day
Study NCT02282592 — intervention group
Intervention type: OTHER
Intervention: Observation about the presence of metabolic syndrome
Study NCT06131476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational lipid eye drops
Description: Test Drops
Study NCT05195697 — intervention group
Intervention type: OTHER
Intervention: Observational study of different treatments and time to treatment
Description: Different treatment based on the clinical decision
Study NCT02744157 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Longterm effects after a structured lifestyle program
Description: present study was to describe a structured intervention to reduce cardiovascular risk in a clinical setting and to study the effects of the program on lifestyle habits and quality of life in individuals at risk after six months and one year.
Study NCT03915873 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The von Willebrand Antigen level
Description: blood sample
Study NCT04927728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Practice
Description: MP is the cognitive rehearsal of a motor task without physical movement, with the intent to improve motor performance. Mental practice can be completed via audio or video recording, visual prompts, written instructions, self-initiated or recorded pictures.
Study NCT04927728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repetitive-Task Practice
Description: Repetitive-Task Practice is the repetitive rehearsal of a motor task with the intent to improve motor performance.
Study NCT04927728 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Therapy
Description: Traditional therapy includes traditional interventions completed in occupational therapy for patients following a stroke. These interventions include but are not limited to, range of motion, weight-bearing, massage, modalities, self-care training, and transfer training.
Study NCT02642094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Low dose of rapamycin at 2 mg/day for -5-7 days of treatment
Study NCT03488160 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-targeted CAR-T cells
Description: This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months..
Study NCT01428817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: 20mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
Study NCT01428817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: 40mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
Study NCT01428817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: 60mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
Study NCT01428817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: 80mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
Study NCT01428817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: 100mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
Study NCT03653598 — intervention group
Intervention type: OTHER
Intervention: Atrial Fibrillation
Description: Data collection on Atrial Fibrillation
Study NCT04336098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRF617
Description: SRF617 prevents CD39 mediated conversion of adenosine triphosphate (ATP) and adenosine diphosphate (ADP) to adenosine monophosphate (AMP) and phosphate, leading to an increase in extracellular ATP and a reduction in adenosine levels within the tumor microenvironment (TME). There is an important role for extracellular ATP and adenosine in cancer maintenance and progression, and maintaining high levels of ATP (and low levels of adenosine) in the TME may have anticancer therapeutic activity.
Study NCT04336098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine as an intravenous (IV) infusion
Study NCT04336098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: Albumin-bound paclitaxel as an IV infusion
Study NCT04336098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab as an IV infusion .
Study NCT04749069 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Comparison of pain intensity rating scale
Description: Comparison of numerical pain intensity rating scale Comparison of faces pain rating scale Comparison of consumption of total amount of remifentanil
Study NCT00838019 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrabone administration of umbilical cord blood
Description: Single administration
Study NCT01162421 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Study drug will be provided to participants in Early Adalimumab arm as a sterile, preservative-free solution for subcutaneous injection, contained in a pre-filled syringe housed in a pen device (pre-filled pen). 40 mg of adalimumab will be administered subcutaneously at Baseline and then every other week for 24 months. Adalimumab may be initiated in participants in standard of care (SOC) arm after a minimum of 6 months of treatment recommended by their study doctor.
Study NCT01357850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK716155
Description: GSK716155
Study NCT01162421 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: adalimumab
Description: Study drug will be provided to participants in Early Adalimumab arm as a sterile, preservative-free solution for subcutaneous injection, contained in a pre-filled syringe housed in a pen device (pre-filled pen). 40 mg of adalimumab will be administered subcutaneously at Baseline and then every other week for 24 months. Adalimumab may be initiated in participants in standard of care (SOC) arm after a minimum of 6 months of treatment recommended by their study doctor.
Study NCT01162421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Participants in both arms will receive a methotrexate regimen based on local guidelines and their study doctor's judgment.
Study NCT01162421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Participants in both arms will receive a methotrexate regimen based on local guidelines and their study doctor's judgment.
Study NCT01357850 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00792571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beraprost Sodium Modified Release
Study NCT00593476 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PCD
Description: pre-packaged, portion-controlled (PCD) meal plan for 24 weeks
Study NCT00593476 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DSE
Description: 12 weeks of diabetes support and education (DSE) (weeks 0-12) and then crosses over to 12 weeks of PCD from weeks 13-24
Study NCT04153708 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Retrieval patients lost to follow-up with positive HCV antibodies without RNA request or positive RNA by phone call.
Description: Patients assigned to strategy 1 will be called to schedule an appointment with the hepatologist over a period of 14 days.